N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.

Key facts

Study ID

NCT00084422

Run by

New Approaches to Neuroblastoma Therapy Consortium

People needed

47

Starts

2003-08-01

Expected to finish

2011-02-01

Last updated by the study team

2023-04-10

Who can join

Age: 0 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Childrens Hospital Los Angeles — Los Angeles, California, United States
• Lucille Salter Packer Children's Hospital, Stanford University — Palo Alto, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus — Atlanta, Georgia, United States
• University of Chicago Comer Children's Hospital — Chicago, Illinois, United States
• Children's Hospital Boston — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Morgan Stanley Children's Hospital of New York-Presbyterian — New York, New York, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
• Hospital for Sick Children — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.